Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells

Area of Science:

• Immunology
• Cancer Biology
• T-cell Dysfunction

Background:

• Standard immunotherapies often fail to induce durable responses in many cancer patients.
• Systemic immune dysfunction in advanced cancer is an underappreciated resistance mechanism.
• Peripheral CD8+ T-cell dysfunction, marked by poor proliferation and chronic immune receptor expression, is linked to minimal response to immunotherapy.

Purpose of the Study:

• To investigate the role of intracellular LAG3 (LAG3IC) in CD8+ T-cell dysfunction and its association with cancer prognosis.
• To explore the mechanisms driving systemic immune dysfunction in cancer patients.
• To identify potential biomarkers for predicting response to immune checkpoint blockade therapies.

Main Methods:

• Analysis of peripheral CD8+ T cells from cancer patients to assess LAG3 expression (intracellular vs. surface).
• Investigation of the role of ADAM10 cleavage in LAG3 regulation.
• Assessment of the impact of IL6 and STAT3 signaling on T-cell function.
• Evaluation of the therapeutic potential of anti-LAG3 blockade.

Main Results:

• Approximately one-third of analyzed cancer patients exhibited high LAG3IC without surface LAG3 (LAG3SUR), linked to poor prognosis.
• This LAG3IC expression was associated with decreased CD8+ T-cell function, partially reversible with anti-LAG3 treatment.
• Systemic immune dysfunction was specific to CD8+ T cells and driven by IL6 via STAT3 signaling.

Conclusions:

• Elevated LAG3IC in CD8+ T cells, coupled with systemic IL6, may serve as predictive biomarkers for immunotherapy response.
• Identifying patients with these markers could guide the use of LAG3 blockade therapies.
• Further research is needed to validate these findings and their clinical utility.